PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales: Elsabah, H., Kassem, N., Gulied, A., Taha, R., Elomri, H., Cherif, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429541/
http://dx.doi.org/10.1097/01.HS9.0000850820.70181.23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429541/
http://dx.doi.org/10.1097/01.HS9.0000850820.70181.23

Ejemplares similares